Determining Best Indications for Bracing for Adolescent Idiopathic Scoliosis
Launched by THE UNIVERSITY OF HONG KONG · Oct 4, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the best ways to use braces for young people with adolescent idiopathic scoliosis (AIS), which is a condition that causes the spine to curve abnormally. The researchers want to find out if starting brace treatment earlier, even for smaller curves, and considering surgery for larger curves is more cost-effective while still keeping patients healthy and happy. They will gather information through questionnaires that ask about health-related quality of life and will also look at the costs involved in treatments. The goal is to help doctors make better decisions about when and how to start bracing for their patients.
To participate in this study, individuals must be diagnosed with adolescent idiopathic scoliosis and still have growth potential, as determined by specific criteria. The study is open to all genders, and participants will need to wear a specific type of brace as part of their treatment. Those who do not have AIS, cannot attend follow-ups, or refuse to participate will not be included. This research could lead to better care for AIS patients in Hong Kong and around the world.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are diagnosed with adolescent idiopathic scoliosis and are seen in the first setting with remaining growth potential (Risser 0-2), and are prescribed with either underarm (Boston) or Milwaukee bracing
- Exclusion Criteria:
- • Patients whose diagnosis is not adolescent idiopathic scoliosis, unable to comply with study follow-up and refused consent for study
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Jason Cheung, MBBS, MS
Principal Investigator
HKU/HA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials